Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2021-11-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
关于重大资产购买暨关联交易之标的资产完成过户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of the transfer of major assets related to a significant asset purchase and related party transaction by 盈康生命科技股份有限公司. It details the transaction completion, payment status, legal and financial advisor opinions, and subsequent steps. The document is a formal announcement of the completion of a major asset acquisition and related disclosures, not the full transaction report or financial statements. It fits the category of Capital/Financing Update (CAP) as it relates to a major asset purchase and related party transaction update.
2021-11-19 Chinese
关于出售长春盈康医院有限公司100%股权及相关债权暨关联交易完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a transaction involving the sale of 100% equity and related debt of a subsidiary company. It details the transaction overview, approval by the board and shareholders, the transaction price, and confirmation that the transaction has been completed including receipt of payment. There is no financial report or detailed financial statements included, nor is it a regulatory certification or a brief report publication notice. The content fits the category of Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes, specifically the sale of a subsidiary's equity and related debt.
2021-11-16 Chinese
关于重大资产重组实施进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a major asset restructuring by 盈康生命科技股份有限公司. It details the acquisition of 100% equity in 苏州广慈肿瘤医院有限公司, including payment details and approvals from board meetings and a shareholders' meeting. The document does not contain financial statements or detailed financial analysis but rather updates on the implementation status of a significant transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including major asset restructurings.
2021-11-12 Chinese
2021年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2021 third extraordinary general meeting of shareholders of 盈康生命科技股份有限公司. It includes detailed voting results on multiple proposals related to a major asset restructuring and related transactions. The document contains specific voting percentages, attendance details, and the outcomes of each agenda item. This matches the description of a Declaration of Voting Results & Voting Rights Announcements (DVA), which is the official results from shareholder votes at any general meeting. The document is lengthy and contains substantive voting data, not just a brief announcement or a reference to another report. Therefore, it is not a Report Publication Announcement or Regulatory Filing. It is not a full Annual Report, Audit Report, or Management Report, nor is it a proxy solicitation or investor presentation. The focus on voting results and resolutions passed at a shareholders meeting clearly classifies it as DVA.
2021-11-10 Chinese
2021年第三次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and procedures of a company's 2021 third extraordinary shareholders' meeting. It details the convening, attendance, voting procedures, and results of the shareholders' meeting, including approval of various resolutions related to a major asset restructuring and related transactions. The document focuses on the validation and certification of the shareholders' meeting process and voting outcomes, which is typical of a Declaration of Voting Results & Voting Rights Announcements filing. It is not an annual report, audit report, or management report, nor is it a proxy solicitation or a general regulatory filing. The detailed voting results and legal opinion on the meeting's legitimacy align with the DVA category.
2021-11-10 Chinese
关于出售杭州怡康中医肿瘤医院有限公司100%股权及相关债权暨关联交易完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a transaction involving the sale of 100% equity and related debt of a subsidiary company. It details the transaction overview, approval by the board and shareholders, the price, and the completion of the transfer and registration. There is no financial report or detailed financial statements included, nor is it a regulatory certification or a brief report publication notice. The content fits the category of a Capital/Financing Update as it relates to a significant change in the company's capital structure through the sale of a subsidiary and related debt. The document length is short and focused on the transaction completion, which aligns with CAP filings.
2021-11-09 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.